News
ZSAN
--
0.00%
--
Zosano Pharma to Present at the H.C. Wainwright Virtual Global Investment Conference
FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. ...
GlobeNewswire · 09/02 20:30
28 Stocks Moving in Thursday's Pre-Market Session
Gainers Focus Universal Inc. (NASDAQ: FCUV) rose 39.7% to $26.93 in pre-market trading after jumping 278% on Wednesday. Focus Universal recently priced 2 million shares at $5 per share to raise $10 million for its initial public offering on the Nasdaq.
Benzinga · 09/02 11:06
BRIEF-Zosano Pharma Posts Q2 Loss Per Share Of $0.06
reuters.com · 08/10 21:38
Zosano Pharma Q2 EPS $(0.06) Up From $(0.14) YoY, Sales $188.00K
Zosano Pharma (NASDAQ:ZSAN) reported quarterly losses of $(0.06) per share. This is a 57.14 percent increase over losses of $(0.14) per share from the same period last year. The company reported $188.00 thousand in
Benzinga · 08/10 20:08
Zosano Pharma Corporation (ZSAN) Reports Q2 Loss, Misses Revenue Estimates
Zacks.com · 08/10 04:44
Zosano Pharma Posts Trial Titled 'Crossover Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers' To ClinicalTrials.Gov
https://clinicaltrials.gov/ct2/show/NCT04969497
Benzinga · 07/20 14:53
BRIEF-Zosano Pharma Receives Patent For Method Of Use Of M207 For Acute Treatment Of Migraine
reuters.com · 07/20 14:28
Zosano Pharma granted patent related to migraine treatment M207
Zosano Pharma (ZSAN) announced that it has been granted an additional patent covering method of use of M207 for the acute treatment of migraine.The patent covers methods for the release
Seekingalpha · 07/20 12:51
Zosano Pharma Announces Issuance Of U.S. Patent For Method Of Rapidly Achieving Therapeutic Levels With M207 For The Acute Treatment Of Migraine
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has been granted an additional patent covering method of use of M207 with the issuance of U.S. Patent No.
Benzinga · 07/20 12:32
Zosano Pharma Announces Issuance of U.S. Patent for Method of Rapidly Achieving Therapeutic Levels with M207 for the Acute Treatment of Migraine
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has been granted an additional patent covering method of use of M207 with the issuance of U.S. Patent No. 11,058,630 titled Method of Rapidly Achie...
GlobeNewswire · 07/20 12:30
15 Best Penny Stocks to Buy Now
In this article, we discuss the 15 best penny stocks to buy now. If you want to skip our detailed analysis of these companies, go directly to the 5 Best Penny Stocks to Buy Now. Many novice investors are bullish on penny stocks with growth potential for ca...
Insider Monkey · 07/14 13:11
BRIEF-Zosano Pharma Corp Files For Mixed Shelf Of Upto $150 Mln
reuters.com · 07/02 22:20
22 Stocks Moving in Tuesday's Pre-Market Session
Gainers Exela Technologies, Inc. (NASDAQ: XELA) rose 39% to $2.05 in pre-market trading after gaining over 5% on Monday.
Benzinga · 06/29 11:05
BRIEF-Zosano Pharma Enters Into A Controlled Equity Offering Sales Agreement
reuters.com · 06/28 22:03
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers SCWorx (NASDAQ:WORX) shares rose 8.38% to $1.81 during Monday's after-market session. SCWorx's trading volume hit 504.7K shares by close, accounting for 148.37% of its average volume over the last 100 days. The market value of their outstanding sha...
Benzinga · 06/28 20:31
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Benzinga · 06/11 20:32
Is Zosano Pharma (NASDAQ:ZSAN) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Simply Wall St. · 06/11 13:35
Sierra Oncology Welcomes Two New Independent Directors to its Board
COMTEX_387786867/2669/2021-06-03T10:04:40
CNW Group · 06/03 14:04
BRIEF-Zosano Pharma Gets Nasdaq Notification Regarding Minimum Bid Price Deficiency
reuters.com · 06/01 21:08
Why Zosano Pharma's Stock Is Trading Higher Today
Zosano Pharma (NASDAQ:ZSAN) shares are trading higher after the company announced publication of clinical data regarding the long-term use of Qtrypta for the treatment of acute migraine in The Journal of Headache and Pain.
Benzinga · 05/27 19:34
Webull provides a variety of real-time ZSAN stock news. You can receive the latest news about Zosano Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ZSAN
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The Company is focused on providing systemic administration of therapeutics to patients using its ransdermal microneedle system (the System). The System is designed to facilitate drug absorption into the bloodstream. The Company’s lead product candidate is Qtrypta (M207). Qtrypta is a formulation of zolmitriptan delivered utilizing its System. Zolmitriptan is a serotonin receptor agonists known as triptans and is used as an acute treatment for migraine. Qtrypta is designed for absorption of zolmitriptan into the bloodstream without dependence on the gastrointestinal (GI) tract. Its same formulation, development name C213, is the treatment to provide relief for cluster headache.